Novartis
Pharmaceutical Company
WHO Investigates Cases Of H1N1 Drug Resistance In U.S., Britain...Thailand and Vietnam, posing once again a threat to humans" (McIntyre, 11/25). Novartis Opens Vaccine Plant In U.S.; Production Of Flu Vaccine Years Away Also on Tuesday, Swiss drug maker Novartis opened a vaccine-manufacturing plant in... In this article: H1N1, United States, Oseltamivir, Novartis, Britain, Medical advice, Dog, Google map, and Norwegian Institute of Public Health |
-
BusinessWeek Online | November 03, 2009
Novartis to Spend $1.25B on China R&D
...market, the Swiss drug giant will pump big money into two R&D centers By Dexter Roberts Novartis (NVS) is betting big on China. On Nov. 3, the Swiss pharmaceutical giant announced it plans to invest $1.25 billion in a pair of...
In this article: China, Daniel Vasella, Shanghai, Revenue, U.S., Beijing, China Investment, Cancer, and State Council
-
Indiana Times - The Economic Times | November 03, 2009
Novartis buys China vaccine stake
...presence in the fast-growing market. Emerging markets are a sweet spot for companies such as Novartis, which said earlier this week it was investing $1.25 billion in research facilities in China. Novartis said on Wednesday the...
In this article: Novartis AG, China, Diovan, and Zurich
-
FT.com - Companies | November 03, 2009
Novartis to expand Chinese research labs
...in our operations, while in other countries it means less," said Mr Vasella. Novartis moved its research base from Basel to Cambridge, Massachusetts, in 2004. Mr Vasella said the experience in Cambridge "taught us that you have to go where...
In this article: Daniel Vasella, Shanghai, China, Cambridge, Basel, Revenue, Cardiovascular disease, Cancer, and GlaxoSmithKline
-
Seeking Alpha | November 05, 2009
Novartis Joins Global Interest in Vaccines with Increased China Investments
Novartis Joins Global Interest in Vaccines with Increased China Investments by: ChinaBio Today November 05, 2009 | about: NVS Novartis (NYSE: NVS) continued its mega-investments in China by announcing it will spend $250 million to expand...
In this article: China, Revenue, Meningitis, Japanese Encephalitis, NYSE, Suzhou, and Shanghai
-
Prime Newswire | November 05, 2009
TapImmune Signs License Agreement With Crucell N.V.
...and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, Sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with...
In this article: Cancer, Cholera, Private Securities Litigation Reform Act of 1995, Hepatitis A, CSL, Crucell, and Wyeth
-
MarketWatch.com - MarketPulse | November 04, 2009
Novartis to buy 85% of Chinese vaccines producer
...to conditions including regulatory clearance in China. On Tuesday, Novartis had said that it planned to invest $1 billion over five years for research and development in China. /marketstate/country/ The market is open3:13:18 am The...
In this article: MarketWatch, China, Tel Aviv, and Basel
-
China Is Growth Market for Novartis
...2009 | about: NVS The Swiss pharmaceutical giant Novartis (NVS) said it will invest $1 billion in China over the next five years including a significant expansion of the company's biomedical research institute in Shanghai. On the heels of the...
In this article: China, Shanghai, Supply chain, Pharmaceutical, and Daniel Vasella
Trends
Loading...
More on Novartis
Description from Wikipedia:
Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number one in revenues, which accounted over $53 billion in 2008, and number three in sales, which accounted 36.172 billon in 2008 . Novartis is one of the largest healthcare companies in the world and a leading giant among pharmaceutical companies. Novartis manufactures drugs such as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), cyclosporin A (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Novartis owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007. Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
- Name:
- Novartis International AG
- Type:
- Public (, NYSE: NVS)
- Location:
- Basel, Switzerland
- Founded:
- 1996 (from merger)
- Stock Symbol:
- NVS
- Industry:
- Pharmaceutical industry
- Key People:
- Daniel Vasella
- Products:
- Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...)
- Revenue:
- US $41.46 billion
- Operating Income:
- US $8.96 billion
- Net Income:
- US $8.16 billion
- No. of Employees:
- 96,700
- Subsidiaries:
- Ciba Vision, Sandoz
Explore everything named Novartis...
